sanofi
Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
Sanofi Workers Strike Over Consumer Health Unit Sale Amid Job Loss and Strategic Asset Concerns
Sanofi, strike, consumer health unit, sale, job losses, strategic assets, France, Doliprane, Opella, Clayton Dubilier & Rice
Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results
Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody
GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply
BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health
Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal
Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition
Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD
Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron
Sanofi Receives Bids from Private Equity Firms for $16B+ Consumer Health Business
Sanofi, private equity firms, consumer health business, PAI Partners, Clayton, Dubilier & Rice, Bloomberg
Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.
Sanofi Prepares for Regulatory Submission of Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib, BTK inhibitor, Multiple sclerosis, Non-relapsing secondary progressive multiple sclerosis (nrSPMS), Sanofi, HERCULES study, GEMINI 1 and 2 studies, Regulatory approval